SCHEMBL6570223

SCHEMBL6570223

CCOC(=O)N1c2cc(OC)c(OC)cc2C(N(Cc2cc(Cl)cc(Cl)c2)C(=O)OC)CC1C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CETP P11597 7/20 0.49
PTGDR2 Q9Y5Y4 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
PDE4B Q07343 1/20 0.32
PDE4D Q08499 1/20 0.32
HTR2A P28223 1/20 0.32
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CNR2 P34972 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL992955 1.00 CETP (0.49) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6594430 1.00 CETP (0.49) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6596573 0.95 CETP (0.44) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6596575 0.95 CETP (0.44) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6596570 0.95 CETP (0.44) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6588649 0.92 CETP (0.48) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6588653 0.92 CETP (0.48) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6588656 0.92 CETP (0.48) CETPPTGDR2NPSR1CA12CA1
SCHEMBL6592640 0.92 CETP (0.59) CETP
SCHEMBL6592643 0.92 CETP (0.59) CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453544-A2 SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2004-09-08 EP claimed
WO-2003000295-A2 SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2003-01-03 WO claimed
EP-2305217-B1 Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors BEND RES INC (US) 2014-07-30 EP disclosed
EP-1469831-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2004-10-27 EP disclosed
EP-0987251-B1 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors PFIZER PROD INC (US) 2004-05-19 EP disclosed
WO-2003000235-A9 PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS PFIZER PROD INC (US) 2003-12-24 WO disclosed
WO-2003063832-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2003-08-07 WO disclosed
US-6362198-B1 ANTICHOLESTEROL, ANTILIPEMIC AGENT PFIZER INC. 2002-03-26 US disclosed
US-6140342-A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR; USED TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN OTHER PLASMA LIPID LEVELS, SUCH AS LDL-CHOLESTEROL AND TRIGLYCERIDES PFIZER INC. (US) 2000-10-31 US disclosed
EP-0987251-A1 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors Pfizer Products Inc. (US) 2000-03-22 EP disclosed